The relationship between telomere length and therapy-associated cytogenetic responses in patients with chronic myeloid leukemia

Cancer

Volumn 79, Issue 8, 1997, Pages 1552-1560

  Iwama, Hiroshi ^a   Ohyashiki, Kazuma ^a   Ohyashiki, Junko H ^a   Hayashi, Shigefumi ^a   Kawakubo, Ken ^a   Shay, Jerry W ^b   Toyama, Keisuke ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

chronic myeloid leukemia; cytogenetic response; interferon; telomerase; telomere

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; ALPHA INTERFERON; HYDROXYUREA; MEPACRINE MUSTARD; TELOMERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BONE MARROW CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOGENETICS; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MONONUCLEAR CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RESTRICTION FRAGMENT; TELOMERE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MIDDLE AGED; REPETITIVE SEQUENCES, NUCLEIC ACID; TELOMERASE; TELOMERE;

EID: 0030900214     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970415)79:8<1552::AID-CNCR17>3.0.CO;2-X     Document Type: Article

References (37)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703.
2. Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 1987; 69:1280-8.
3. Kloke O, Niederle N, Qiu JY, Wandl U, Moritz T, Nagel-Hiemke M, et al. Impact of Interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemia. Br J Haematol 1993;83:399-403.
4. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant α2b Interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 1993;82:2975-84.
5. Allan NC, Richards SM, Shepherd PCA. UK medical research council randomized, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995;345:1392-7.
6. n, present at the telomeres of human chromosomes. Proc Natl Acad Sci USA 1988;85:6622-6.
7. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990;345:458-60.
8. Allsopp RC, Vaziri H, Patterson C, Goldstein S, Younglai EV, Futcher AB, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci USA 1992;89:10114-8.
9. Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM. Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proc Natl Acad Sci USA 1994;91:9857-60.
10. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mutat Res 1991;256:271-82.
11. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with aging. Nature 1990;346:866-8.
12. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266:2011-5.
13. Counter CM, Gupta J, Harley CB, Leber B, Bacchetti S. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood 1995;85:2315-20.
14. Hiyama K, Hirai Y, Koizumi S, Akiyama M, Hiyama E, Piatyszek MA, et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995;155:3711-5.
15. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995;92:9082-6.
16. Shay JW. Aging and cancer: are telomeres and telomerase the connection? Mol Med Today 1995;1:378-84.
17. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985;43:405-13.
18. Morin GB. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989;59:521-9.
19. Blackburn EH. Telomerases. Annu Rev Biochem 1982; 61:113-9.
20. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Shay JW, Toyama K. Telomerase reactivation in leukemia cells. Int J Oncol 1996;8:417-21.
21. Shay JW, Werbin H, Wright WE. Telomere shortening may contribute to aging and cancer. A perspective. Mol Cell Diff 1994;2:1-21.
22. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality, and cancer. Cold Spring Harb Symp Quant Biol 1994;59:307-15.
23. Piatyszek MA, Kim NW, Weinrich SL, Hiyama K, Hiyama E, Wright WE, et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci 1995;17:1-15.
24. Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994;54:3557-60.
25. ISCN. Guidelines for cancer cytogenetics: supplement to An International System for Human Cytogenetic Nomenclature. In Mitelman F, editor. Basel: S. Karger, 1991.
26. Ohyashiki JH, Ohyashiki K, Toyama K, Shay JW. A non-radio-active fluorescence-based telomeric repeat amplification protocol to detect and quantitate telomerase activity. Trends Genet 1996;12:395-6.
27. Wright WE, Shay JW, Piatyszek MA. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity and sensitivity. Nucleic Acids Res 1995;23:3794-5.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
29. Fujimura T. Telomere shortening in hematopoietic neoplasias and its clinical implications. J Tokyo Med Coll 1995;53:652-63.
30. Yamada O, Oshimi K, Motoji T, Mizoguchi H. Telomeric DNA in normal and leukemic blood cells. J Clin Invest 1995;95:1117-23.
31. Ohyashiki K, Ohyashiki JH, Iwama H, Hayashi S, Kawakubo K, Toyama K. Telomerase reactivation, shrinking telomeres, and cytogenetic alterations in chronic myeloid leukemia with disease evolution. Blood 1995;86(Suppl 1):738a.
32. Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J Cancer Res 1992;83:159-64.
33. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nature Med 1995; 1:249-55.
34. Kawakubo K, Ohyashiki K, Ohyashiki JH, Shimamoto T, Fujimura T, Iwama H, et al. A possible correlation between interferon-stimulated gene expression and cytogenetic responses in chronic myeloid leukemia patients treated with α-interferon. Jpn J Clin Oncol 1996;26:59-64.
35. De Mel WCP, Hoffbrand AV, Giles FJ, Goldstone AH, Mehta AB, Ganeshaguru K. Alpha Interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response. Br J Haematol 1990;74:452-6.
36. Clauss IM, Vandenplas B, Wathelet MG, Dorval C, Delforge A, Content T, et al. Analysis of interferon-inducible genes in cells of chronic myeloid leukemia patients responsive or resistant to an interferon-α treatment. Blood 1990;76:2337-42.
37. Talpaz M, Chernajovsky Y, Troutman-Worden K, Wetzler M, Kantarjian H, Gutterman JU, et al. Interferon-stimulated genes in interferon-sensitive and -resistant chronic myelogenous leukemia patients. Cancer Res 1992;52:1087-90.